145643-15-8

Upstream product

• 145643-14-7 (S)-N-((S)-1-tert-Butoxycarbonyl-2-phenyl-ethyl)-3-[5-(4-carbamimidoyl-phenyl)-pentanoylamino]-succinamic acid tert-butyl ester 
• 591-80-0 pent-4-enoic acid 
• 623-00-7 4-bromobenzenecarbonitrile 
• 145643-09-0 5-(p-cyanophenyl)-4-pentenoic acid 
• 145643-10-3 5-(p-Cyanophenyl)-pentanoic acid 
• 145643-11-4 5-(p-cyanophenyl)pentanoyl-(S)-aspartyl(O-tert-butyl)-(S)-phenylalanine(O-tert-butyl) 
• 145643-12-5 (S)-N-((S)-1-tert-Butoxycarbonyl-2-phenyl-ethyl)-3-[5-(4-thiocarbamoyl-phenyl)-pentanoylamino]-succinamic acid tert-butyl ester 

Relevant academic research and scientific papers

Phenyl amidines derivatives useful as platelet aggregation inhibitors

This invention relates to phenyl amidine derivatives having the following formula STR1 or a pharmaceutically acceptable salt which are useful in the inhibition of platelet aggregation. This invention also relates to pharmaceutical compositions of such phe

Potent in vitro and in vivo inhibitors of platelet aggregation based upon the Arg-Gly-Asp-Phe sequence of fibrinogen. A proposal on the nature of the binding interaction between the Arg-guanidine of RGDX mimetics and the platelet GP IIb-IIIa receptor

Peptide mimetics of the RGDF sequence in which Arg-Gly has been replaced with 5-(4-amidinophenyl)pentanoyl mimetic has led to a 1000-fold increase in inhibitory potency over the natural RGDF ligand. The guanidine residue of the arginine may be involved in